NASDAQ:JNCE Jounce Therapeutics (JNCE) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.88▼$1.9350-Day Range$1.84▼$1.9452-Week Range$0.58▼$5.87Volume11.60 million shsAverage Volume2.46 million shsMarket Capitalization$98.94 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Jounce Therapeutics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside219.1% Upside$6.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthGrowingFrom ($1.71) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector300th out of 982 stocksBiological Products, Except Diagnostic Industry43rd out of 162 stocks 3.1 Analyst's Opinion Consensus RatingJounce Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Jounce Therapeutics has a forecasted upside of 219.1% from its current price of $1.88.Amount of Analyst CoverageJounce Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for JNCE. Previous Next 0.0 Dividend Strength Dividend YieldJounce Therapeutics does not currently pay a dividend.Dividend GrowthJounce Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJounce Therapeutics has received a 75.46% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Jounce Therapeutics is -0.67. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Jounce Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Jounce Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jounce Therapeutics insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $65,044.00 in company stock and sold $72,572.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by InsidersOnly 6.92% of the stock of Jounce Therapeutics is held by insiders.Percentage Held by Institutions80.66% of the stock of Jounce Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Jounce Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jounce Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jounce Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJounce Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jounce Therapeutics (NASDAQ:JNCE) StockJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Read More Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JNCE Stock News HeadlinesJune 2, 2023 | americanbankingnews.comJounce Therapeutics (NASDAQ:JNCE) Receives New Coverage from Analysts at StockNews.comMay 25, 2023 | americanbankingnews.comJounce Therapeutics (NASDAQ:JNCE) Now Covered by Analysts at StockNews.comJune 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 19, 2023 | americanbankingnews.comJounce Therapeutics (NASDAQ:JNCE) Earns Hold Rating from Analysts at StockNews.comMay 10, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Jounce Therapeutics (NASDAQ:JNCE)May 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 4, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock OptionsJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 4, 2023 | benzinga.comJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock OptionsMay 3, 2023 | finance.yahoo.comJounce Therapeutics Announces Closing of Tender OfferMay 1, 2023 | americanbankingnews.comJounce Therapeutics (NASDAQ:JNCE) Coverage Initiated by Analysts at StockNews.comApril 29, 2023 | seekingalpha.comJNCE Jounce Therapeutics, Inc.April 25, 2023 | americanbankingnews.comAnalysts Set Jounce Therapeutics, Inc. (NASDAQ:JNCE) PT at $8.00April 17, 2023 | finance.yahoo.comThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableMarch 31, 2023 | americanbankingnews.comJounce Therapeutics, Inc. (NASDAQ:JNCE) Receives $8.00 Average Price Target from BrokeragesMarch 29, 2023 | benzinga.comWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?March 29, 2023 | americanbankingnews.comJounce Therapeutics (NASDAQ:JNCE) Downgraded to "Neutral" at Piper SandlerMarch 27, 2023 | msn.comBuyout Offer Sends Jounce Jumping 20%March 27, 2023 | marketwatch.comJounce Therapeutics Shares Rally on Buyout Deal >JNCEMarch 27, 2023 | marketwatch.comJounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCEMarch 27, 2023 | finance.yahoo.comJounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsMarch 23, 2023 | benzinga.comMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law FirmMarch 23, 2023 | americanbankingnews.comJounce Therapeutics (NASDAQ:JNCE) Stock Rating Lowered by StockNews.comMarch 17, 2023 | 247wallst.comTang Capital Partners Now Owns 10.2% of Jounce TherapeuticsMarch 16, 2023 | finance.yahoo.comJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerMarch 16, 2023 | finance.yahoo.comJounce (JNCE) Up 41% on Buyout Offer From Concentra BiosciencesSee More Headlines JNCE Company Calendar Last Earnings11/04/2021Today6/07/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JNCE CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone(857) 259-3840FaxN/AEmployees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+219.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,920,000.00 Net MarginsN/A Pretax Margin-61.93% Return on Equity-30.90% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio8.37 Quick Ratio8.37 Sales & Book Value Annual Sales$82 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value$3.54 per share Price / Book0.53Miscellaneous Outstanding Shares52,630,000Free Float48,993,000Market Cap$98.94 million OptionableOptionable Beta0.75 Key ExecutivesKimberlee Cobleigh DrapkinPresident, Chief Financial Officer & TreasurerEric LaubHead-Investor & Media RelationsTed HardingSenior Vice President-Human ResourcesJacquelyn Fahey SandellSecretary & Chief Legal OfficerAllison NanceVP-Regulatory Affairs & Quality AssuranceKey CompetitorsGenenta ScienceNASDAQ:GNTATalaris TherapeuticsNASDAQ:TALSOrchard TherapeuticsNASDAQ:ORTXPrecision BioSciencesNASDAQ:DTILOcugenNASDAQ:OCGNView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 886,639 shares on 5/18/2023Ownership: 2.160%Geode Capital Management LLCBought 96,655 shares on 5/16/2023Ownership: 1.458%Jane Street Group LLCBought 108,127 shares on 5/16/2023Ownership: 0.239%Susquehanna International Group LLPBought 79,005 shares on 5/16/2023Ownership: 0.206%Colony Group LLCBought 25,000 shares on 5/16/2023Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions JNCE Stock - Frequently Asked Questions Should I buy or sell Jounce Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" JNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNCE, but not buy additional shares or sell existing shares. View JNCE analyst ratings or view top-rated stocks. What is Jounce Therapeutics' stock price forecast for 2023? 4 brokers have issued 12-month target prices for Jounce Therapeutics' shares. Their JNCE share price forecasts range from $3.00 to $11.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 219.1% from the stock's current price. View analysts price targets for JNCE or view top-rated stocks among Wall Street analysts. When is Jounce Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our JNCE earnings forecast. How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.15. During the same period in the previous year, the firm posted ($0.73) earnings per share. What ETF holds Jounce Therapeutics' stock ? IQ Merger Arbitrage ETF holds 1,024,423 shares of JNCE stock, representing 0.35% of its portfolio. What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO? 45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR). When did Jounce Therapeutics IPO? (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. What is Jounce Therapeutics' stock symbol? Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE." Who are Jounce Therapeutics' major shareholders? Jounce Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.84%), JPMorgan Chase & Co. (2.16%), BML Capital Management LLC (2.09%), State Street Corp (1.53%), Geode Capital Management LLC (1.46%) and Beryl Capital Management LLC (1.16%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kevin C Tang, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third. View institutional ownership trends. What is Jounce Therapeutics' stock price today? One share of JNCE stock can currently be purchased for approximately $1.88. How much money does Jounce Therapeutics make? Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $98.94 million and generates $82 million in revenue each year. The company earns $-50,920,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. How many employees does Jounce Therapeutics have? The company employs 137 workers across the globe. How can I contact Jounce Therapeutics? Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com. This page (NASDAQ:JNCE) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.